AU2001270475A1 - Modulators of protein tyrosine phosphatases (ptpases) - Google Patents

Modulators of protein tyrosine phosphatases (ptpases)

Info

Publication number
AU2001270475A1
AU2001270475A1 AU2001270475A AU7047501A AU2001270475A1 AU 2001270475 A1 AU2001270475 A1 AU 2001270475A1 AU 2001270475 A AU2001270475 A AU 2001270475A AU 7047501 A AU7047501 A AU 7047501A AU 2001270475 A1 AU2001270475 A1 AU 2001270475A1
Authority
AU
Australia
Prior art keywords
protein tyrosine
tyrosine phosphatases
ptpases
modulators
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001270475A
Inventor
Henrik Sune Andersen
Frank Urban Axe
Farid Bakir
Yu Ge
Thomas Kruse Hansen
Daniel Dale Holsworth
Luke Milburn Judge
Jesper Lau
Niels Peter Hundahl Moller
Michael James Newman
Ole Hvilsted Olsen
Barry Zvi Shapira
Roy Teruyuki Uyeda
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novo Nordisk AS
Ontogen Corp
Original Assignee
Novo Nordisk AS
Ontogen Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk AS, Ontogen Corp filed Critical Novo Nordisk AS
Publication of AU2001270475A1 publication Critical patent/AU2001270475A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Abstract

The present invention provides novel thienopyridines, where such compounds of Formula 1 are pharmacologically useful inhibitors of Protein Tyrosine Phosphatases (PTPase's) including PTP1B, T cell PTP; wherein X, R1, R2, R3 and R4 are defined more fully in the description. The compounds are useful in the treatment of type diabetes, type 2 diabetes, impaired glucose tolerance, insulin resistance, obesity, and other diseases.
AU2001270475A 2000-07-07 2001-06-28 Modulators of protein tyrosine phosphatases (ptpases) Abandoned AU2001270475A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA200001068 2000-07-07
DKPA200001068 2000-07-07
PCT/DK2001/000451 WO2002004459A1 (en) 2000-07-07 2001-06-28 Modulators of protein tyrosine phosphatases (ptpases)

Publications (1)

Publication Number Publication Date
AU2001270475A1 true AU2001270475A1 (en) 2002-01-21

Family

ID=8159610

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001270475A Abandoned AU2001270475A1 (en) 2000-07-07 2001-06-28 Modulators of protein tyrosine phosphatases (ptpases)

Country Status (6)

Country Link
EP (1) EP1301516B1 (en)
JP (1) JP2004502775A (en)
AT (1) ATE321052T1 (en)
AU (1) AU2001270475A1 (en)
DE (1) DE60118195T2 (en)
WO (1) WO2002004459A1 (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1147214B1 (en) 1999-01-13 2011-01-05 The Research Foundation Of State University Of New York A novel method for designing protein kinase inhibitors
HUP0400183A2 (en) * 2001-06-11 2004-07-28 Xenoport Inc. Orally administered dosage forms of gaba analog prodrugs having reduced toxicity
US7186855B2 (en) 2001-06-11 2007-03-06 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US6818787B2 (en) 2001-06-11 2004-11-16 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US8048917B2 (en) 2005-04-06 2011-11-01 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
CA2464214C (en) * 2001-10-22 2011-02-08 The Research Foundation Of State University Of New York Protein kinase and phosphatase inhibitors, methods for designing them, and methods of using them
US7005445B2 (en) 2001-10-22 2006-02-28 The Research Foundation Of State University Of New York Protein kinase and phosphatase inhibitors and methods for designing them
PL372848A1 (en) 2002-04-03 2005-08-08 Novartis Ag 5-substituted 1,1-dioxo-[1,2,5]thiazolidine-3-one derivatives as ptpase 1b inhibitors
EP1628970A2 (en) * 2003-04-30 2006-03-01 The Institutes of Pharmaceutical Discovery, LLC Heterocycle substituted carboxylic acids as inhibitors of protein tyrosine phosphatase-1b
EA200501710A1 (en) 2003-04-30 2006-06-30 ДЗЕ ИНСТИТЬЮТС ФОР ФАРМАСЬЮТИКАЛ ДИСКАВЕРИ, ЭлЭлСи SUBSTITUTED CARBON ACIDS
US7521473B2 (en) 2004-02-25 2009-04-21 Wyeth Inhibitors of protein tyrosine phosphatase 1B
JP5043645B2 (en) 2004-04-07 2012-10-10 メルク セローノ ソシエテ アノニム carboxylic acid
RU2440112C2 (en) 2004-11-04 2012-01-20 Ксенопорт, Инк. Delayed-release oral dosage form of gabapentin
AU2005307718A1 (en) * 2004-11-18 2006-05-26 The Institutes For Pharmaceutical Discovery, Llc Heterocycle substituted carboxylic acids for the treatment of diabetes
US7838542B2 (en) 2006-06-29 2010-11-23 Kinex Pharmaceuticals, Llc Bicyclic compositions and methods for modulating a kinase cascade
CN114478430B (en) * 2022-02-21 2023-11-28 山东大学 Spore thiazole compounds and preparation method and application thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999046244A1 (en) * 1998-03-12 1999-09-16 Novo Nordisk A/S Modulators of protein tyrosine phosphatases (ptpases)
JP2004500308A (en) * 1998-03-12 2004-01-08 ノボ　ノルディスク　アクティーゼルスカブ Modulator of protein tyrosine phosphatase
JP2002506073A (en) * 1998-03-12 2002-02-26 ノボ ノルディスク アクティーゼルスカブ Modulators of protein tyrosine phosphatase (PTPases)
WO1999046267A1 (en) * 1998-03-12 1999-09-16 Novo Nordisk A/S Modulators of protein tyrosine phosphatases (ptpases)
EP1214060A2 (en) * 1999-09-10 2002-06-19 Novo Nordisk A/S Method of inhibiting protein tyrosine phosphatase 1b and/or t-cell protein tyrosine phosphatase and/or other ptpases with an asp residue at position 48
AU6985200A (en) * 1999-09-10 2001-04-17 Novo Nordisk A/S Modulators of protein tyrosine phosphatases (ptpases)
EP1214325B1 (en) * 1999-09-10 2005-11-09 Novo Nordisk A/S MODULATORS OF PROTEIN TYROSINE PHOSPHATASES (PTPases)

Also Published As

Publication number Publication date
EP1301516B1 (en) 2006-03-22
DE60118195T2 (en) 2006-12-14
WO2002004459A1 (en) 2002-01-17
DE60118195D1 (en) 2006-05-11
JP2004502775A (en) 2004-01-29
ATE321052T1 (en) 2006-04-15
EP1301516A1 (en) 2003-04-16

Similar Documents

Publication Publication Date Title
AU6985200A (en) Modulators of protein tyrosine phosphatases (ptpases)
AU6985300A (en) Modulators of protein tyrosine phosphatases (ptpases)
AU2001270475A1 (en) Modulators of protein tyrosine phosphatases (ptpases)
BR9913532A (en) New heteroaromatic inhibitors of fructose 1,6-bisphosphatase
BR0017048A (en) Phosphonate bisamidate prodrugs
SE0001899D0 (en) New compounds
MY136764A (en) Indole-3-carboxamides as glucokinase (gk) activators
RS93604A (en) Substituted phenylacetamides and their use as glucokinase activators
WO2001069222A3 (en) Implantable analyte sensor
EP1062507B8 (en) Determination of white blood cell differential
MXPA04004842A (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1.
IL161154A0 (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
DK0833839T3 (en) Heterocyclic peptidyl compounds useful in the treatment of thrombin-related diseases
NZ517439A (en) Glucopyranosyloxypyrazole derivatives, medicinal compositions containing the same and intermediates in the production thereof
AU2002238737A1 (en) Glycyrrhetinic acid derivatives, progesterone and progesterone derivatives and their use for the manufacture of a medicament to inhibit 11beta-hydroxysteroid dehydrogenase activity
AU2002351593A1 (en) Pharmaceutical compositions comprising unacylated ghrelin and therapeutical uses thereof
AU2001289457A1 (en) Methods and compositions employing a novel stearoyl-coa desaturase-hscd5
CA2374003A1 (en) Improved cellular uptake of bioactive agents
ATE350385T1 (en) NEW ARYL FRUCTOSE-1,6-BISPHOSPHATASE INHIBITORS
MX9708621A (en) 'beta'-ADRENERGIC AGONISTS.
EP1143955A3 (en) A COMBINATION OF FBPase INHIBITORS AND INSULIN SENSITIZERS FOR THE TREATMENT OF DIABETES
BR0316324A (en) Interferon-alpha polypeptides and conjugates
RS44204A (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
RS44304A (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
AU5539899A (en) Novel triazolo(4,5-(d))pyrimidine compounds